4DMEDICAL LIMITED (4DX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

4DX

4DX - 4DMEDICAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.1
Index: ALL-TECH

4DMedical is a global medical technology company specialising in the treatment of lung disease through respitory imaging and analysis. The company has facilities in Melbourne and Los Angeles. It listed on the ASX in 2020.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.595

03 Nov
2025

-0.145

OPEN

$1.73

-8.33%

HIGH

$1.74

4,801,499

LOW

$1.59

TARGET
$2.075

+0.60 change from previous day

 30.1% upside
OTHER COMPANIES IN THE SAME SECTOR
AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
4DX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 7.1 - 4.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-7.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx5.9 M
Book Value Per Share xxxxxxxxxxxxxxx13.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-34.5 M
Net Profit Margin xxxxxxxxxxxxxxx-513.72 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-44.49 %
Return on Invested Capital xxxxxxxxxxxxxxx-42.19 %
Return on Assets xxxxxxxxxxxxxxx-27.99 %
Return on Equity xxxxxxxxxxxxxxx-44.49 %
Return on Total Capital xxxxxxxxxxxxxxx-65.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-34.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx43 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx7 M
Price To Book Value xxxxxxxxxxxxxxx1.74

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxxxxxxxx23.02 %
Cost of Goods Sold xxxxxxxxxxxxxxx38 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

23/10/2025

2

Downgrade to Accumulate from Speculative Buy

$1.90

19.12%

Ord Minnett downgrades 4DMedical to Accumulate from Speculative Buy, with a new target price of $1.90 from 75c, noting a positive 1Q26 period, including FDA approval of CT:VQ and CMS reimbursement approval at US$650 per scan.

The cash position also improved, up $39m versus the previous quarter, which was down -$7m.

More insights are expected at the upcoming September quarter update, as well as ongoing CT:VQ contract announcements and possible updates from the Radiological Society of North America 2025 event in November.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.20 cents.
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.80 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

4DX STOCK CHART

FNArena News on 4DX

1
Weekly Ratings, Targets, Forecast Changes – 24-10-25

Oct 27 2025 - Weekly Reports
2
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
3
FNArena Corporate Results Monitor – 03-09-2025

Sep 03 2025 - Australia
4
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
5
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps

Latest Medical Equipment & Devices News

1
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
2
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
3
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
4
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
5
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
6
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
7
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
8
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
9
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
10
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia